|
Mycophenolic acid
|
A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.
|
ILX:0107261
|
4
|
FDI Lab - SciCrunch.org
|
06/12/2021
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Mydriatic Agent Code Sequence
|
The actual agent administered to dilate the pupil.
|
ILX:0107262
|
6
|
FDI Lab - SciCrunch.org
|
08/28/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
troy sincomb |
|
Myelin Associated Protein
|
|
ILX:0107263
|
4
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Myelin Basic Protein
|
A group of 7 proteins produced from a single gene by alternate splicing found in central and peripheral nervous system myelin. The major basic protein (MBP) has long been of interest because it is the antigen, that, when injected into an animal, elicits a cellular immune response that produces the CNS autoimmune disease called experimental allergic encephalomyelitis (encephalomyelitis, allergic). In the peripheral nervous system, myelin basic protein 18.5 kD is often referred to as the P1 protein. (From Siegel et al., Basic Neurochemistry, 5th ed, p130, 133) (MSH)
|
ILX:0107264
|
4
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Myelin staining protocol
|
A technique used to selectively alter the appearance of myelin (sheaths) that surround the nerve cell axons.
|
ILX:0107265
|
5
|
FDI Lab - SciCrunch.org
|
01/17/2023
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Myobath Tissue Bath
|
Tissue baths include multi-channel isolated tissue bath systems for the in vitro study of vascular and non-vascular smooth muscle.
|
ILX:0107266
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Myoclonic Epilepsy
|
A clinically diverse group of epilepsy syndromes characterized either by myoclonic seizures or by myoclonus in association with other seizure types. Myoclonic epilepsy syndromes are divided into three subtypes based on etiology: familial, cryptogenic, and symptomatic (i.e., occurring secondary to known disease processes such as infections, hypoxic-ischemic injuries, trauma, etc.) (MeSH).
|
ILX:0107267
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Myoclonus
|
Involuntary shock-like contractions, irregular in rhythm and amplitude, followed by relaxation, of a muscle or a group of muscles. This condition may be a feature of some CENTRAL NERVOUS SYSTEM DISEASES; (e.g., EPILEPSY, MYOCLONIC). Nocturnal myoclonus is the principal feature of the NOCTURNAL MYOCLONUS SYNDROME.
|
ILX:0107268
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Myopic chorioretinal atrophy
|
|
ILX:0107269
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Myosin
|
A diverse superfamily of proteins that function as translocating proteins. They share the common characteristics of being able to bind ACTINS and hydrolyse MgATP. Myosins generally consist of heavy chains which are involved in locomotion, and light chains which are are involve in regulation. Within the structure of myosin heavy chain are three domains: the head, the neck and the tail. The head region of the heavy chain contains the actin binding domain and MgATPase domain which provides energy for locomotion. The neck region is involved in binding the light-chains. The tail region provides the anchoring point that maintains the position of the heavy chain. The superfamily of myosins is organized into structural classes based upon the type and arrangement of the subunits they contain (MSH).
|
ILX:0107270
|
4
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Myotis
|
|
ILX:0107271
|
5
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Myotonic Dystrophy
|
Myotonic dystrophy is the most common adult form of muscular dystrophy, although it can strike at any age. It is marked by myotonia (an inability to relax muscles after contraction) and muscle wasting and weakness. Myotonic dystrophy varies in its severity and manifestations. It can affect other body systems in addition to skeletal muscles, including the heart, endocrine organs, eyes, and gastrointestinal tract.
|
ILX:0107272
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Mysticeti
|
|
ILX:0107273
|
4
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
N-Acetyl-D-glucosamine
|
The N-acetyl derivative of glucosamine. (PubChem) Pharmacology: Not Available Mechanism of action: The mechanism of action in relieving arthritic pain and in repair of cartilage is a matter of speculation. Biochemically, glucosamine is involved in glycoprotein metabolism. Glycoproteins, known as proteoglycans, form the ground substance in the extra-cellular matrix of connective tissue. Proteoglycans are polyanionic substances of high-molecular weight and contain many different types of heteropolysaccharide side-chains covalently linked to a polypeptide-chain backbone. These polysaccharides make up to 95% of the proteoglycan structure. In fact, chemically, proteoglycans resemble polysaccharides more than they do proteins. The polysaccharide groups in proteoglycans are called glycosaminoglycans (GAGs). GAGs include hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin and heparan sulfate. All of the GAGs contain derivatives of glucosamine or galactosamine. Glucosamine derivatives are found in hyaluronic acid, keratan sulfate and heparan sulfate. Chondroitin sulfate contains derivatives of galactosamine. The glucosamine-containing glycosaminoglycan hyaluronic acid is vital for the function of articular cartilage. GAG chains are fundamental components of aggrecan found in articular cartilage. Aggrecan confers upon articular cartilage shock-absorbing properties. It does this by providing cartilage with a swelling pressure that is restrained by the tensile forces of collagen fibers. This balance confers upon articular cartilage the deformable resilience vital to its function. In the early stages of degenerative joint disease, aggrecan biosynthesis is increased. However, in later stages, aggrecan synthesis is decreased, leading eventually to the loss of cartilage resiliency and to most of the symptoms that accompany osteoarthritis. During the progression of osteoarthritis, exogenous glucosamine may have a beneficial role. It is known that, in vitro, chondrocytes do synthesize more aggregan when the culture medium is supplemented with glucosamine. N-acetylglucosamine is found to be less effective in these in vitro studies. Glucosamine has also been found to have antioxidant activity and to be beneficial in animal models of experimental arthritis. The counter anion of the glucosamine salt (i.e. chloride or sulfate) is unlikely to play any role in the action or pharmacokinetics of glucosamine. Further, the sulfate in glucosamine sulfate supplements should not be confused with the glucosamine sulfate found in such GAGs as keratan sulfate and heparan sulfate. In the case of the supplement, sulfate is the anion of the salt. In the case of the above GAGs, sulfate is present as an ester. Also, there is no glucosamine sulfate in chondroitin sulfate (source: PDRhealth). Drug type: Approved. Nutraceutical. Small Molecule. Drug category: Dietary supplement. Micronutrient
|
ILX:0107274
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
N-acylglucosamine 2-epimerase
|
A protein that is a translation product of the RENBP gene or a 1:1 ortholog thereof.
|
ILX:0107275
|
7
|
FDI Lab - SciCrunch.org
|
10/24/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
troy sincomb |
|
N-back task
|
A task in which items (e.g., letters) are presented one at a time and participants must identify each item that repeats relative to the item that occurred "n" items before its onset.
|
ILX:0107276
|
7
|
FDI Lab - SciCrunch.org
|
09/07/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
troy sincomb |
|
N-formyl-L-Met-L-Leu-L-Phe
|
|
ILX:0107277
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
N-formylpeptide receptor
|
|
ILX:0107278
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
N-formylpeptide receptor - unspecified 1
|
|
ILX:0107279
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
N-formylpeptide receptor - unspecified 2
|
|
ILX:0107280
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |